Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech

Can biotech keep its breathless IPO pace? A look at the numbers

By Damian Garde

Fred Hutchinson Cancer Research Center
Business

How life sciences companies are using AI — and how to separate hope from hype

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Rolle Blood Vessel 02
In the Lab

‘Living Legos’ form blood vessels to simulate heart disease and test drugs

By Elizabeth Cooney

The Readout LOUD

LISTEN: Sarepta’s gene therapy coup, Theranos’ legal defense, and parsing hype in AI

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Genetic Testing Immigration
Biotech

Could genetic testing help reunite separated immigrant families? It’s complicated

By Rebecca Robbins

Health

Can this doctor figure out how to stop Alzheimer’s before it starts?

By Joshua Kendall

Biotech

Startups aim to make allies of human gut’s microbes

By Jonathan Saltzman — Boston Globe

Sarepta - hearing
Biotech

What Sarepta’s game-changing data mean for biotech’s other Duchenne players

By Damian Garde

In the Lab

Archived chat: last week in CRISPR — cancer, patents, and a dip in the market

By Sharon Begley

Sarepta
Biotech

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

By Adam Feuerstein

Red blood cells
Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

In the Lab

Synthesizing genetic sequences could get faster, one DNA letter at a time

By Karen Weintraub

Eric Schmidt
Biotech

CAR-T startup Allogene Therapeutics picks up veteran analyst Eric Schmidt as CFO

By Adam Feuerstein

Biotech

New drug for spinal muscular atrophy shows positive results — and could be a threat to Biogen

By Adam Feuerstein

Elizabeth Holmes
Biotech

Theranos founder Elizabeth Holmes indicted for alleged fraud, out as CEO

By Rebecca Robbins and Damian Garde

Biotech

China just approved its first cancer immunotherapy drug. Here’s what’s next in the pipeline

By Rebecca Robbins

Sickle cell Bluebird Update
Biotech

New Bluebird data show promising benefits for gene therapy, if they last

By Adam Feuerstein

CRISPR Cancer Risk
Biotech

Why reports about CRISPR’d cells and cancer aren’t calamitous — but shouldn’t be ignored

By Sharon Begley

The Readout LOUD

LISTEN: Problematic parties, NASH nitpicks, and an intimate look at the opioid crisis

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Cellular Authophagy
Business

Is it time to target autophagy to treat disease? 

By Elizabeth Cooney

Nasdaq
Biotech

What to watch for in biotech for the rest of 2018

By Damian Garde and Adam Feuerstein

Biotech

Topless women with company logos painted on their bodies danced at unofficial party during BIO convention

By Rebecca Robbins

Fatty Liver Drawing
Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Sad child
Biotech

Sage Therapeutics gets ‘go faster’ permission from FDA on oral depression drug

By Adam Feuerstein

Crispr DNA
Biotech

CRISPR scientists are in for the long haul. Wall Street is less patient

By Damian Garde

In the Lab

A serious new hurdle for CRISPR: Edited cells might cause cancer, two studies find

By Sharon Begley

Biotech

For smaller companies, a presence at BIO conference is a big deal

By Jonathan Saltzman — Boston Globe

The Readout LOUD

LISTEN: Twitter vitriol, biotech jargon, and the plight of the CEO

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Don't Miss

BIO in 30: A new biotech from Gates, Bradner on data science, & bienvenue à Cambridge

By Helen Branswell, Adam Feuerstein, and Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy